Department of Obstetrics and Gynaecology

Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies (2020) Schneeweiss A, Hartkopf AD, Mueller V, Woeckel A, Lux MP, Janni W, Ettl J, et al. Journal article, Review article Pembrolizumab for early triple-negative breast cancer (2020) Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J, Denkert C, et al. Journal article Discrimination analysis of breast calcifications using x-ray dark-field radiography (2020) Rauch T, Rieger J, Pelzer G, Horn F, Erber R, Wunderle M, Emons J, et al. Journal article Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer (2020) Slamon DJ, Neven P, Chia S, Fasching P, De Laurentiis M, Im SA, Petrakova K, et al. Journal article Phase III PAOLA-1/ENGOT-OV25 Trial: Olaparib Plus Bevacizumab (BEV) As Maintenance Therapy in Patients (PTS) with Newly Diagnosed, Advanced Ovarian Cancer (OC) Treated with Platinum-Based Chemotherapy (PCH) Plus Bev (2020) De Gregorio N, Harter P, Sehouli L, Canzler U, Marme F, Buderath P, Lueck HJ, et al. Conference contribution Germline (G)BRCA1/2 Mutations (M) and Hematological Toxicities in Patients (PTS) with Triple Negative Breast Cancer (TNBC) Treated with Neoadjuvant Chemotherapy (NACT) (2020) Furlanetto J, Moebus V, Schneeweiss A, Rhiem K, Tesch H, Blohmer JU, Luebbe K, et al. Conference contribution A Randomized, Double-Blind, Phase III Trial of Neoadjuvant Chemotherapy (NACT) with atezolizumab/Placebo in Patients with Triple-Negative Breast Cancer (TNBC) Followed by Adjuvant Continuation of atezolizumab/Placebo (Gepardouze) (2020) Loibl S, Jackisch C, Seiler S, Rastogi P, Huober L, Denkert C, Schneeweiss A, et al. Conference contribution Germline Mutation Status and Therapy Response in High-Risk Early-Stage Breast Cancer: a Secondary Analysis of the Geparocto Randomized Clinical Trial (NCT02125344) (2020) Pohl-Rescigno E, Hauke J, Rhiem K, Moebus V, Furlanetto J, Denkert C, Fasching P, et al. Conference contribution First Results of the Detect IVA Study -Everolimus Treatment in Patients with HER2-Negative, Hormone-Receptor Positive Metastatic Breast (MBC) Cancer and Circulating Tumor Cells (CTC) (2020) Friedl TWP, Krause S, Fasching P, Schneeweiss A, Mueller V, Riethdorf S, Taran FA, et al. Conference contribution Is there an Advantage of Lymphadenectomy for Overall and Recurrence-Free Survival in Endometrial Carcinoma Type I FIGO IB G1-2? A Retrospective Population-Based Cohort Analysis (2020) Hassas D, Papathemelis T, Gerken M, Scharl S, Scharl A, Lux MP, Beckmann M, et al. Conference contribution